SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is caught in a sharp memory-stock selloff as traders weigh Chinese competitor CXMTs planned DRAM products, a steep Korean market decline, and broader worries about AI valuations and interest rates. The community is split between viewing the competition and market pressure as signs of a deeper downturn and calling the drop an overreaction given Microns AI-memory demand and fundamentals.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves selloff is being tied to Gartners warning that many neocloud providers may not remain independent as AI infrastructure spending outpaces revenue, alongside concerns about the companys debt and sharply higher yields on its bonds; hot inflation and rate worries added pressure. Traders are split between fears of financing strain and AI overbuild and arguments that the drop is overdone given demand and backlog, with dip buyers facing bearish calls.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSMCs strong Q3 results and upbeat outlook are drawing attention, but the shares are falling amid a broader semiconductor selloff and concerns about AI spending, valuations, and whether strong results were already priced in. Some traders see the results as evidence of resilient AI demand, while others argue that risk-off sentiment and capex concerns are outweighing the fundamentals.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is under pressure as a semiconductor selloff coincides with hotter-than-expected inflation and worries about AI valuations and Chinese chip competition, despite traders pointing to strong chip-company results and demand. The community is split between buying what some see as an overdone pullback and expecting further declines, with the ETFs 3x leverage amplifying the swings.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs Neutron first flight has been pushed to 2027 after manufacturing defects were found in a carbon-composite tank component, intensifying concerns about repeated delays, execution, and postponed growth. Traders are divided between viewing the schedule slip as a prudent safety decision and seeing it as a setback that undermines confidence and the stocks valuation.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

A broad South Korean semiconductor selloff has pressured SK Hynix amid concerns about Chinese rival CXMTs memory advances and the durability of AI spending. Traders disagree on whether the competitive threat is meaningful soon, with bullish voices arguing it is distant and that HBM demand remains strong.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is caught in a sharp selloff across neocloud and AI-infrastructure stocks after Gartner warned that heavy AI spending may outpace revenue and many independent providers could struggle to survive; hotter inflation and financing concerns added pressure. Traders are divided between buying the dip on long-term AI demand and fearing an AI-capex bubble, costly funding, and further downside.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention as shares slide amid hotter-than-expected inflation and rising energy costs, with traders linking the pressure to the Iran conflict and Trump administration policies. Most discussion is bearish and focused on political and market risks, though some traders are looking for a potential bounce.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is under pressure amid a prolonged semiconductor selloff, with traders citing inflation and interest-rate concerns alongside doubts about AI spending returns and rising Chinese competition. The community is split between expecting further technical downside and viewing the sharp decline as an oversold dip-buying opportunity.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure amid a prolonged semiconductor selloff, with traders citing hotter inflation and rate concerns alongside doubts about AI spending returns and possible sector rotation. The discussion is bearish on broken charts and continued downside, though some traders see the decline as an oversold dip-buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Quantum BioPharma (NASDAQ: QNTM) Enlists Thermo Fisher’s Clinical Research Business to Launch Phase 2 Lucid-MS Trial

Most multiple sclerosis (“MS”) drugs work by quieting the immune system. A new partnership shines the spotlight on a different approach — protecting the nerve’s own insulation — and sets up that treatment for a rigorous clinical test. Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has signed a [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial

Quantum BioPharma (NASDAQ: QNTM) entered into a Study Start-Up Agreement (&#8220;SUA&#8221;) with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302 (&#8220;Lucid-MS&#8221;) for multiple sclerosis (&#8220;MS&#8221;). The agreement initiates formal study start-up activities following FDA clearance to proceed with the trial. Thermo Fisher will support study start-up [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing

A green light from the U.S. Food and Drug Administration (“FDA”) can turn years of laboratory work into a real shot at treating patients, and that is exactly what just happened for one biopharmaceutical company. Quantum BioPharma (NASDAQ: QNTM), a company focused on neurodegenerative and metabolic disorders, announced that the FDA has approved its Investigational [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

Nearly three million people around the world wake up every day managing a disease that has no cure, and the number keeps climbing. That reality is what makes new approaches to multiple sclerosis worth paying attention to, and it is the space where Quantum BioPharma (NASDAQ: QNTM) is working to make a difference with its [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target

Disseminated&#160;on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Quantum BioPharma&#160;(NASDAQ: QNTM),&#160;a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, announced that Rodman &#38; Renshaw&#160;initiated&#160;coverage of the company with a Buy rating and&#160;a&#160;$8 price target. The research report was led by Michael G. King Jr., director of research and senior [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit

Disseminated&#160;on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Quantum BioPharma&#160;(NASDAQ: QNTM)&#160;a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, announced its participation in the 3rd Annual&#160;ArcStone-Kingswood Growth Summit on Sept. 16, 2026, in Toronto, where Co-founder and Executive Co-chairman Anthony Durkacz will present the company’s recent milestones and future [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential

Disseminated&#160;on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)&#160;received a ‘Buy’ rating from&#160;Rodman &#38; Renshaw, which initiated coverage with an $8.00 price target based on the company’s Lucid-MS drug candidate. Described as a potentially first-in-class non-immunomodulatory small molecule, Lucid-MS is being developed to address neurodegeneration and disability progression [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Multiple sclerosis (“MS”) treatment has traditionally focused on controlling the immune activity that drives new inflammatory lesions and relapses. While this approach has transformed the management of relapsing MS, growing attention is being directed toward another fundamental challenge: protecting the nervous […]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2

This article has been disseminated on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM)&#160;reported second-quarter 2026 financial and operational results, including a 53% year-over-year reduction in operating expenses to $2.29 million and a 47% decrease in general and administrative expenses to $1.76 million. Combined cash, cash equivalents and digital [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis

This article has been disseminated on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Multiple sclerosis is quietly shifting how drugmakers define success. Instead of judging a therapy mainly by whether it reduces relapses, developers are chasing the slower, harder-to-treat processes that drive long-term disability, and&#160;Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM)&#160;is one of the companies [&#8230;]

Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. It operates through the Biopharmaceutical and Strategic Investments segments. The Biopharmaceutical segment focuses on furthering the research and development of the drug candidates and the development of a treatment for alcohol misuse for application in hospitals and other medical practices. The Strategic Investments segment is involved in the generation of returns and cash flow through the issuance of loans secured by residential property, with FSD Strategic Investments having a first or second collateral mortgage on the secured property. The company was founded by Thomas Fairfull, Zeeshan Saeed, and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Quantum BioPharma Ltd. - Ordinary Shares - Class B (Sub Voting)

Why Did QNTM Stock Pop In Pre-Market Today?

Equity

Bearish Sentiment

Hotter than expected

As expected

Cooler than expected

The September Producer Price Index report lands Thursday, October 15 at 8:30 AM ET, one day after CPI, with August’s reading at 5.4% year over year, as investors look for clues on inflation before the Fed’s October 27-28 meeting. How will the September PPI print compare to consensus expectations? Vote and explain your reasoning in the comments.

How will the September PPI print compare to consensus expectations?

Current Price	$2.66
Prev Close	$2.89
Open	$2.85
Dividend Yield	0.00%
50-Day Moving Average	$3.37
Beta	1.22
Avg. Volume	199,615.06
PE Ratio	-0.47

52-Week High	$15.50
52-Week Low	$2.07
Market Capitalization	$23.37M
EPS (Annual)	-$7.97
Price to Book	2.54
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

QNTM Fundamentals